The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease
The Centers for Medicare & Medicaid Services (CMS) announced broader Medicare coverage of LEQEMBI
· New research collaboration brings together world-leading institutions’ collective expertise in therapeutics, technology, health data, technology commercialisation and advanced analytics/data science in neurology.
· Two-year pilot provides a launch pad for translating scientific prototypes into practical solutions that demonstrate real-world impact.
· NEURii collaboration builds on Eisai’s extensive experience in delivering innovative treatments in neurology and supports ongoing contributions to the global digital health ecosystem.
On June 26th, Tencent Healthcare and Eisai China signed a strategic cooperation agreement. The two parties will use Tencent Healthcare’s pharmaceutical industry SaaS solution – NGES (Next Generation Engagement Suite), a one-stop management platform for physician interaction as a base, by deeply integrating Tencent’s connectivity advantages and digital technology with Eisai China’s core scenarios of customer management, multi-channel marketing and conference event management, Eisai China will realize a new paradigm of online and offline integration of academic communication, in order to help Eisai China open up the whole domain scenarios, link up “application islands”, continue to cultivate the Chinese market with management upgrade and model innovation, and achieve high-quality development.
ACHIEVEMENT OF OUTCOME INDICATORS IN FY2022 PAY FOR SUCCESS CONTRACT
Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer’s disease
The PDUFA action date for traditional approval of LEQEMBI has been set for July 6, 2023, with designation of priority review
LEQEMBI received accelerated approval from the FDA for the treatment of early Alzheimer’s disease on January 6, 2023
Reviewed by China Quality Certification Center, the Suzhou Factory of Eisai China Inc (hereinafter referred to as the “Suzhou Factory”) has successfully passed the GB/T23331-2020/ISO50001: 2018 Energy Management System Certification and obtained the Certificate. This marks significant achievements in the construction of the energy management system and production energy-saving management of Suzhou Factory in scientific, lean and standardized aspects.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO?), will be given at the 37th annual meeting of the Associated Professional Sleep Societies (SLEEP 2023), to be held from June 3 to 7, 2023 in Indianapolis, IN, the United States.
After four years of follow-up, LENVIMA plus KEYTRUDA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial
Final results will be presented at ASCO 2023 in an oral abstract session
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that it will grant a total of 625 million yen to the Global Health Innovative Technology Fund (“GHIT Fund”) to fund the third phase of its activities, which will take place in the five-year period from FY2023 to FY2027. The GHIT Fund is a public-private partnership, co-established in April 2013 by partners such as Japanese pharmaceutical companies (including Eisai), the Japanese government, and the Bill & Melinda Gates Foundation, for the purpose of accelerating development of new medicines to cure infectious diseases in developing and emerging countries by facilitating collaboration between research organizations in Japan and overseas. Eisai has provided a total of 1 billion yen to the first phase (FY2013 – FY2017) and the second phase (FY2018 – FY2022) of the GHIT Fund.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO23), which is taking place virtually and in-person in Chicago, Illinois from June 2 to 6.
